Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

People with diabetes should eat as much protein as people who don't have diabetes. In a healthy diet, roughly 10% to 35% of your daily calories should come from protein. Protein itself does not have ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the ...

Whether to block or stimulate GIP has become a hot debate in obesity research. Some scientists hypothesize that stimulating GIP, as Zepbound does, could desensitize the protein on pancreatic cells ...

Sage Ther­a­peu­tics knows it needs to do some­thing. But it doesn’t want to sell to its part­ner Bio­gen.

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Ei­sai and Bio­gen scored an ap­proval for once-month­ly IV main­te­nance dos­ing of their Alzheimer’s drug Leqem­bi, as part of what they’ve said is an on­go­ing … ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...